Core Insights - PacBio reported preliminary unaudited revenue for Q4 2025 of $44.6 million, reflecting a 14% year-over-year growth, and full-year revenue of $160.0 million, representing a 4% increase compared to 2024 [1][2] Financial Performance - Q4 2025 revenue breakdown includes: - Instrument revenue of approximately $17.3 million, up from $15.3 million in Q4 2024 - Consumable revenue of approximately $21.6 million, an increase from $18.8 million in Q4 2024 - Service and other revenue of approximately $5.7 million, compared to $5.1 million in Q4 2024 [2] - Full-year 2025 revenue breakdown includes: - Instrument revenue of approximately $53.8 million, down from $65.8 million in 2024 - Consumable revenue of approximately $81.9 million, up from $70.3 million in 2024 - Service and other revenue of approximately $24.3 million, compared to $17.9 million in 2024 [2] Product Performance - The company placed 21 Revio systems and 42 Vega systems in Q4 2025, compared to 23 and 7 placements respectively in Q4 2024 - For the full year 2025, 61 Revio systems and 140 Vega systems were placed, down from 97 and 7 placements in 2024 [2] - The annualized Revio pull-through per system was approximately $242,000 in Q4 2025, slightly up from $240,000 in Q4 2024 [2] Strategic Outlook - The CEO highlighted strong momentum from increased sales of Revio and Vega systems, along with record consumables revenue, indicating traction in clinical sequencing applications - The company aims to reduce cash burn and strengthen its financial profile, with expectations for growth driven by real-world evidence and lower costs from the SPRQ-Nx technology in 2026 and beyond [2]